Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2022 Results assessing efficacy and safety of neoadjuvant avelumab/axitinib in patients with localized renal cell carcinoma, presented at the 2022 Genitourinary Cancers Symposium.
08 Jun 2021 Results (n=24) assessing early dynamic changes in the tumour immune environment after neoadjuvant treatment with avelumab/axitinib, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com